First data generated in U.S. support Theraclion’s Echotherapy system

First data generated in U.S. support Theraclion’s Echotherapy system

Press releases may be edited for formatting or style | August 31, 2016 Ultrasound

An ongoing, single-arm study of patients with thyroid nodules, showed that the mean percent of volume reduction at three months and at 12 months after echotherapy were 47.4% ± 20.8% and 55.5% ± 28.4%, respectively, in group 1 (only one session) and were 24.2% ± 15.8% and 46.0% ± 22.0%, respectively, in group 2 (two sessions). (Abstract ID: CA-51)
About Theraclion

Theraclion is a French company specializing in high-tech medical equipment using therapeutic ultrasound. Drawing on leading-edge technologies, Theraclion has designed and manufactured an innovative solution for echotherapy, the Echopulse®, allowing non-invasive tumor treatment through ultrasound-guided high-intensity focused ultrasound. Theraclion is ISO 13485 certified and has received the CE mark for non-invasive ablation of breast fibroadenomas and thyroid nodules. Based in Malakoff, near Paris, France Theraclion has brought together a team of 34 people, 50% of whom are dedicated to R&D and clinical trials. For more information, please visit Theraclion’s website:

Amber Diagnostics - New Flat Panel Digital Detector Available for OEC 9800!

With this new technology, you can make the transition to digital without breaking the bank. Ultra High Resolution Radiography and Fluoroscopy. Enjoy the high DQE of CMOS technology. No additional wiring or training required. Click here to request pricing!

DOTmed 100
Theraclion is listed on Alternext Paris
PEA-PME eligible
Mnemonic: ALTHE - ISIN Code: FR0010120402

Back to HCB News

You Must Be Logged In To Post A Comment